PURPOSE: To identify prognostic molecular profiles in patients with mRCC treated with sunitinib, we performed immunohistochemical analysis for VEGF and PI3K/Akt/mTOR pathway components. METHODS: The immunohistochemical expression of VEGF, p85α, p110γ, PTEN, p-Akt, p-mTOR, p-4E-BP1 and p-p70S6K was studied in 79 patients with mRCC who received first-line treatment with sunitinib. Expression was correlated with clinicopathological features and survival. RESULTS: VEGF was highly expressed (median H-Score 150), while positivity for the markers of the PI3K/Akt/mTOR pathway was: p85α 43/66 (65 %), p110γ41/60 (68 %), PTEN 32/64 (50 %), p-Akt57/63 (90 %), p-mTOR48/64 (75 %), p-4E-BP1 58/64 (90 %) and p-p70S6K 60/65 (92 %). No single immunohistochemical marker was found to have prognostic significance. Instead, the combination of increased p-mTOR and low VEGF expression was adversely correlated with overall survival (OS) (3.2 vs. 16.9 months, P = 0.001). CONCLUSION: Immunohistochemistry for VEGF and p-mTOR proteins may discriminate patients refractory to first-line sunitinib with poor prognosis. Prospective validation of our findings is needed.
PURPOSE: To identify prognostic molecular profiles in patients with mRCC treated with sunitinib, we performed immunohistochemical analysis for VEGF and PI3K/Akt/mTOR pathway components. METHODS: The immunohistochemical expression of VEGF, p85α, p110γ, PTEN, p-Akt, p-mTOR, p-4E-BP1 and p-p70S6K was studied in 79 patients with mRCC who received first-line treatment with sunitinib. Expression was correlated with clinicopathological features and survival. RESULTS:VEGF was highly expressed (median H-Score 150), while positivity for the markers of the PI3K/Akt/mTOR pathway was: p85α 43/66 (65 %), p110γ41/60 (68 %), PTEN 32/64 (50 %), p-Akt57/63 (90 %), p-mTOR48/64 (75 %), p-4E-BP1 58/64 (90 %) and p-p70S6K 60/65 (92 %). No single immunohistochemical marker was found to have prognostic significance. Instead, the combination of increased p-mTOR and low VEGF expression was adversely correlated with overall survival (OS) (3.2 vs. 16.9 months, P = 0.001). CONCLUSION: Immunohistochemistry for VEGF and p-mTOR proteins may discriminate patients refractory to first-line sunitinib with poor prognosis. Prospective validation of our findings is needed.
Authors: Tobias Klatte; David B Seligson; Jeffrey LaRochelle; Brian Shuch; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz F Kabbinavar; Allan J Pantuck; Arie S Belldegrun Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-24 Impact factor: 4.254
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar Journal: J Clin Oncol Date: 2004-02-01 Impact factor: 44.544
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: J Garcia-Donas; L J Leandro-García; A González Del Alba; M Morente; I Alemany; E Esteban; J A Arranz; M A Climent; E Gallardo; D E Castellano; J Bellmunt; B Mellado; J Puente; F Moreno; A Font; S Hernando; M Robledo; C Rodríguez-Antona Journal: Ann Oncol Date: 2013-06-20 Impact factor: 32.976
Authors: L del Puerto-Nevado; F Rojo; S Zazo; C Caramés; G Rubio; R Vega; C Chamizo; V Casado; J Martínez-Useros; R Rincón; M Rodríguez-Remírez; A Borrero-Palacios; I Cristóbal; J Madoz-Gúrpide; O Aguilera; J García-Foncillas Journal: Br J Cancer Date: 2014-05-01 Impact factor: 7.640
Authors: Robert J Motzer; Thomas E Hutson; Gary R Hudes; Robert A Figlin; Jean-Francois Martini; Patricia A English; Xin Huang; Olga Valota; J Andrew Williams Journal: Cancer Chemother Pharmacol Date: 2014-08-07 Impact factor: 3.333
Authors: Sung Han Kim; Weon Seo Park; Eun Young Park; Boram Park; Jungnam Joo; Jae Young Joung; Ho Kyung Seo; Kang Hyun Lee; Jinsoo Chung Journal: PLoS One Date: 2017-06-27 Impact factor: 3.240
Authors: Si-Young Kiessling; Martina Anja Broglie; Alex Soltermann; Gerhard Frank Huber; Sandro Johannes Stoeckli Journal: Laryngoscope Investig Otolaryngol Date: 2018-08-09